Nightingale Health Misses Revenue Target, Targets EUR10M Next Year

Nightingale Health PLC posted fiscal year 2025-26 revenue of EUR5.5 million, a 17% year-over-year increase. This result fell significantly below the company’s prior target of at least 50% growth. According to materials reviewed by GN markets/earnings (en-US), approximately EUR2 million in expected income from a single large project was delayed due to third-party issues. This specific slip shifted the revenue recognition into the current fiscal year, directly contributing to the miss against the initial forecast.

Despite the annual shortfall, the second half of the fiscal year marked the company’s strongest performance to date. Revenue in that period rose 30% compared to the same time last year. Management attributes this acceleration to the expansion of its preventive healthcare platform, which now supports over 3 million validated samples and more than 1,000 peer-reviewed publications. The business remains debt-free with a stable cash runway, allowing it to continue operations without increasing its cost burden while it works to close the gap between projected and actual figures.

Operational Pipeline Drives New Forecast

For the current fiscal year, Nightingale Health aims to double its revenue to at least EUR10 million. CEO Teemu Suna stated that this projection relies on a combination of traditional operational sales and strategic landmark deals. The company emphasizes that the forecast is grounded in its existing pipeline rather than speculative upside from unsecured contracts. Suna noted that the previous year’s base revenue of EUR5.5 million was achieved without the delayed flagship project, suggesting that the underlying operational engine is capable of supporting the higher target.

The revenue mix is gradually shifting, with the healthcare segment expected to grow its share relative to the research business. However, the research division still constitutes the largest portion of current income. The company operates its own laboratories in the US, UK, Finland, Japan, and Singapore, which reduces dependence on external networks and allows for parallel execution across multiple markets. This infrastructure supports the step-by-step ramp-up of new deals, although management acknowledges that long sales cycles mean significant revenue contributions from new contracts will take time to materialize.

Profitability Remains Distant Goal

Nightingale Health is not yet profitable and has not achieved positive cash flow. The path to profitability is explicitly tied to winning new deals and increasing adoption of its services. Suna explained that the market has transformed due to the pandemic and AI, with demand now focused on connecting molecular data to actual health outcomes. The company’s strategy is to leverage this shift to drive commercial breakthroughs, but it faces the challenge of converting its strong sales pipeline into sustained cash flow without immediate capital concerns.

The company’s financial flexibility allows it to pursue these opportunities without the pressure of debt servicing. However, the vulnerability to external factors, such as the third-party delay that cost EUR2 million in the previous year, highlights the risks in its execution model. As the company moves forward, the balance between operational sales activities and strategic partnerships will determine whether it can achieve the targeted 100% growth and begin the transition toward positive cash flow.